AGP Executive Report
Last update: 7 hours agoGLP-1 Access Push: A JMCP study reports pharmacists running proactive prior authorizations for GLP-1s cut median decision time to about 20 hours, easing delays that can stall care. Cancer Care Evidence Gap: A retrospective analysis aims to clarify how tarlatamab performs in small-cell lung cancer patients with active brain metastases, plus the safety of giving radiation alongside treatment. Immunotherapy Strategy in RCC: Early rationale coverage highlights a phase 1b PRISM trial combining the JAK inhibitor ruxolitinib with PD-1 blockade retifanlimab to help overcome resistance in renal cell carcinoma. CAR T Referral Reality Check: Clinicians discuss misconceptions that delay CAR T referrals in multiple myeloma, including eligibility and toxicity assumptions. Alzheimer’s Genetics Update: New findings show APOE and broader polygenic risk can shift Alzheimer’s onset timing in people with extra APP copies. Public Health & Safety: Pennsylvania expands naloxone and drug-testing distribution to faith-based partners, while an FDA-linked recall chain hits jalapeño products. Vet Health: American Regent recalls specific Adequan lots after glass fibers were found in retained samples.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
Pseudo-journalism: Pink-slime
